pioglitazone has been researched along with Pulmonary Hypertension in 4 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pioglitazone treatment increased oxygen saturation and pTyr14cav-1 vs." | 5.72 | Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension. ( Balis, P; Doka, G; Klimas, J; Kmecova, Z; Krenek, P; Malikova, E; Pivackova, LB; Trubacova, S; Velasova, E, 2022) |
| "Pioglitazone treatment increased oxygen saturation and pTyr14cav-1 vs." | 1.72 | Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension. ( Balis, P; Doka, G; Klimas, J; Kmecova, Z; Krenek, P; Malikova, E; Pivackova, LB; Trubacova, S; Velasova, E, 2022) |
| "Pioglitazone treatment improved survival, reduced PASP, muscularization of small pulmonary arteries, and medial wall thickness." | 1.43 | Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension. ( Baldus, S; Behringer, A; Berghausen, EM; Blaschke, F; Caglayan, E; Er, F; Gassanov, N; Kappert, K; Odenthal, M; Rosenkranz, S; Ten Freyhaus, H; Trappiel, M; Wellnhofer, E, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malikova, E | 1 |
| Kmecova, Z | 1 |
| Doka, G | 1 |
| Pivackova, LB | 1 |
| Balis, P | 1 |
| Trubacova, S | 1 |
| Velasova, E | 1 |
| Krenek, P | 1 |
| Klimas, J | 1 |
| Legchenko, E | 1 |
| Chouvarine, P | 1 |
| Borchert, P | 1 |
| Fernandez-Gonzalez, A | 1 |
| Snay, E | 1 |
| Meier, M | 1 |
| Maegel, L | 1 |
| Mitsialis, SA | 1 |
| Rog-Zielinska, EA | 1 |
| Kourembanas, S | 1 |
| Jonigk, D | 1 |
| Hansmann, G | 1 |
| Lim, GB | 1 |
| Behringer, A | 1 |
| Trappiel, M | 1 |
| Berghausen, EM | 1 |
| Ten Freyhaus, H | 1 |
| Wellnhofer, E | 1 |
| Odenthal, M | 1 |
| Blaschke, F | 1 |
| Er, F | 1 |
| Gassanov, N | 1 |
| Rosenkranz, S | 1 |
| Baldus, S | 1 |
| Kappert, K | 1 |
| Caglayan, E | 1 |
4 other studies available for pioglitazone and Pulmonary Hypertension
| Article | Year |
|---|---|
Pioglitazone restores phosphorylation of downregulated caveolin-1 in right ventricle of monocrotaline-induced pulmonary hypertension.
Topics: Animals; Caveolin 1; Disease Models, Animal; Heart Ventricles; Hypertension, Pulmonary; Male; Monocr | 2022 |
PPARĪ³ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.
Topics: Fatty Acids; Female; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Male; Oxidation-R | 2018 |
Treatment of PAH with a PPARĪ³ agonist.
Topics: Heart Failure; Humans; Hypertension, Pulmonary; Pioglitazone; PPAR gamma | 2018 |
Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Topics: Animals; Arterial Pressure; Cardiovascular Agents; Disease Models, Animal; Fibrosis; Heart Ventricle | 2016 |